MDXG News and Press, MiMedx Group Inc From 12/24/20

Persistent and sustained institutional buying in MiMedx should not be ignored as heavy hitters position themselves for key knee osteoarthritis data in 2021. Sales and revenue growth after two years of floundering could cause additional explosive upside. If you are looking for a de...

Gainers: Nxt-ID (NXTD) +50%.Diginex (EQOS) +48%.Aethlon Medical (AEMD) +40%.MIND Technology (MIND) +27%.Aclaris Therapeutics (ACRS) +24%.Tilray (TLRY) +23%.MiMedx Group (MDXG) +22%.Amyris (AMRS) +21%.Drive Shack (DS) +20%.Marathon Patent Group (MARA) +19%.Losers: Concord Medical Services...

Gainers: Aethlon Medical (AEMD) +47%. Aclaris Therapeutics (ACRS) +32%. Tilray (TLRY) +23%. MiMedx Group (MDXG) +23%. Sio Gene Therapies (SIOX) +21%.Losers: Concord Medical Services Holdings (CCM) -43%. BioLineRx (BLRX) -30%. vTv Therapeutics (VTVT) -22%. Sensus Healthcare (SRTS) -1...

Significant evidence indicates that Amniofix is a highly effective and safe treatment for knee OA, and that the product will likely receive FDA approval for this indication. The RMAT designation further increases Amniofix's chances of being approved, and gives MDXG the opportunity to ...

The Welsh retirement portfolio of stocks updated for the Christmas rally and rebalanced to start 2021 diversified. Reasons why I like each and every stock and thoughts for investing in 2021. 80% of money managers can't outperform the S&P 500 nor my portfolio, and you shouldn't...

MARIETTA, Ga., Dec. 07, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will present at the 39 th Annual J.P...

Thinly traded small cap OrthoPediatrics ([[KIDS]] -7.7%) is under modest pressure in apparent response to a post on social media by Culper Research touting its bearish view.It claims, based on interviews with four distributors and two former executives, that the company is engaging in revenue...

Experienced Healthcare Executive Will Expand Company’s Visibility Within the Financial Community MARIETTA, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound ca...

MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Pet...

MiMedx Group is in the early stages of a sales recovery, after a turbulent last 2 years. 90% of management are new faces, and the new growth strategy dovetails to include commercialization, R&D focus and supply chain integration. Their amniotic hypotheses have high commercial ...